This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
We apologise that we are unable to display a photograph of the packaging or provide you with more information regarding this prescription medicine. Australian legislation prohibits the advertisement of prescription drugs to consumers.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Benazepril hydrochloride 2.5mg|
|Indication||Treatment of heart failure due to mitral valve regurgitation and dilated cardiomyopathy in dogs, chronic kidney disease in cats and dogs, and hypertrophic cardiomyopathy in cats.|
|Actions||Pharmacology Benazepril hydrochloride, a pro-drug, is hydrolysed in vivo to benazeprilat, which inhibits angiotensin converting enzyme (ACE), thus preventing the conversion of inactive angiotensin I into active angiotensin II. Fortekor reduces local and systemic effects mediated by angiotensin II, including vasoconstriction of arteries and veins, and retention of sodium and water by the kidney. Fortekor causes long lasting inhibition of plasma ACE in dogs and cats, with significant inhibition persisting for 24 hours after a single dose.Pharmacokinetics Absorption. Benazepril is rapidly but incompletely absorbed from the gastrointestinal tract following oral administration. Metabolism. Absorbed benazepril is partially hydrolysed by hepatic enzymes to the active substance benazeprilat; unchanged benazepril and hydrophilic metabolites account for the remainder. Distribution. Peak plasma benazeprilat concentrations are attained within about two hours both in fasting and fed situations. Benazepril and benazeprilat are bound to plasma proteins and in tissues are found mainly in the liver and kidney. Repeated administration of Fortekor leads to slight accumulation of benazeprilat in plasma; steady state is attained within four days. Excretion. The major part of benazeprilat is rapidly eliminated, although there is in addition a slow terminal elimination phase. Benazeprilat is excreted approximately equally via the biliary and urinary routes in dogs, and primarily via the biliary route in cats. No dose adjustment of Fortekor is necessary in cases of renal insufficiency.|
|Precautions||Pregnancy, lactation. The safety of Fortekor has not been tested in breeding animals. Fortekor is therefore not recommended for use in pregnant or lactating animals. Fortekor should therefore be used only if justified clinically, considering the risk–benefit ratio.Clinical trials have shown Fortekor to have good renal tolerance. No evidence of renal toxicity of Fortekor has been observed in normal dogs and cats during clinical trials. The biliary excretion of benazeprilat means that there is little risk of bioaccumulation in dogs and cats with impaired renal function. In cats, plasma creatinine concentrations may continue to increase at the start of therapy. This effect is related to the therapeutic effect of the product in reducing glomerular capillary blood pressure and therefore it is not necessarily a reason to stop therapy in the absence of other signs.First Aid If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131 126.|
|Dosage and Administration||Oral doses to be administered once daily with or without food. Dogs. 0.25 mg/kg bodyweight. The dose may be doubled and given once a day if judged by the veterinary surgeon as clinically necessary. Cats. 0.5 mg/kg bodyweight.|
|Storage||Store below 25°C (air conditioning). Protect from heat and moisture. Return unused half-tablets to the opened blister space, insert back into carton and use within two days.|
|MSDS (external link)||Fortekor 2.5mg MSDS|
|Label (external link)||Fortekor 2.5mg Label|
|Manufacturer||Elanco Animal Health|